Recognized standard
C63.24-2021
FDA recognition 19-44 · IEEE · General II (ES/EMC)
Key facts
| Recognition number | 19-44 |
|---|---|
| Designation | C63.24-2021 |
| Title | American National Standard - Recommended Practice for In Situ RF Immunity Evaluation of Electronic Devices and Systems |
| Standards developer | Institute of Electrical and Electronic Engineers |
| Specialty area | General II (ES/EMC) |
| Date of entry | Dec 20, 2021 |
| Scope (excerpt) | This recommended practice provides a method for in situ immunity testing of electronic devices and systems that are installed and operated at the locations where they are used, as well as where they experience interference. The primary source of the electromagnetic (EM) energy is from transmitters… |
At a glance
- None Product codes
- 1–9 FDA guidance documents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-recognized consensus standards
The FDA recognizes voluntary consensus standards that manufacturers can cite in premarket submissions to show conformity with specific requirements.
Source: U.S. Food and Drug Administration (FDA), Recognized Consensus Standards database · Source date: